Search research articles
Contact Us
Filters
Showing results (61-70 of 82) with videos related to
Page
of 9
Sort By:
Viruses
|
August 30, 2018
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection
Teresa I Ng, Tami Pilot-Matias, Rakesh Tripathi, et al.
Contemporary Clinical Trials
|
November 11, 2025
Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIV
Ana Gabriela Pires Dos Santos, Manal Abunimeh, Beatriz Mothe, et al.
The Lancet. Infectious Diseases
|
August 19, 2017
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
Xavier Forns, Samuel S Lee, Joaquin Valdes, et al.
Journal of Gastroenterology
|
November 15, 2017
Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
Hiromitsu Kumada, Tsunamasa Watanabe, Fumitaka Suzuki, et al.
Journal of Gastroenterology
|
October 21, 2017
Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
Hiromitsu Kumada, Tsunamasa Watanabe, Fumitaka Suzuki, et al.
Hepatology (Baltimore, Md.)
|
September 20, 2017
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial
David Wyles, Fred Poordad, Stanley Wang, et al.
The Lancet. Gastroenterology & Hepatology
|
July 20, 2020
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)
Lai Wei, Guiqiang Wang, Negar N Alami, et al.
Annals of Hepatology
|
September 19, 2020
Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil
Mario Peribañez-Gonzalez, Hugo Cheinquer, Lino Rodrigues, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 27, 2016
Discovery of fluorobenzimidazole HCV NS5A inhibitors
John T Randolph, Charles A Flentge, Pamela Donner, et al.
Antimicrobial Agents and Chemotherapy
|
November 1, 2017
<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir
Teresa I Ng, Rakesh Tripathi, Thomas Reisch, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 82) with videos related to
Sort By:
Page
of 9
Viruses
|
August 30, 2018
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection
Teresa I Ng, Tami Pilot-Matias, Rakesh Tripathi, et al.
Contemporary Clinical Trials
|
November 11, 2025
Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIV
Ana Gabriela Pires Dos Santos, Manal Abunimeh, Beatriz Mothe, et al.
The Lancet. Infectious Diseases
|
August 19, 2017
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial
Xavier Forns, Samuel S Lee, Joaquin Valdes, et al.
Journal of Gastroenterology
|
November 15, 2017
Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
Hiromitsu Kumada, Tsunamasa Watanabe, Fumitaka Suzuki, et al.
Journal of Gastroenterology
|
October 21, 2017
Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
Hiromitsu Kumada, Tsunamasa Watanabe, Fumitaka Suzuki, et al.
Hepatology (Baltimore, Md.)
|
September 20, 2017
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial
David Wyles, Fred Poordad, Stanley Wang, et al.
The Lancet. Gastroenterology & Hepatology
|
July 20, 2020
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)
Lai Wei, Guiqiang Wang, Negar N Alami, et al.
Annals of Hepatology
|
September 19, 2020
Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil
Mario Peribañez-Gonzalez, Hugo Cheinquer, Lino Rodrigues, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 27, 2016
Discovery of fluorobenzimidazole HCV NS5A inhibitors
John T Randolph, Charles A Flentge, Pamela Donner, et al.
Antimicrobial Agents and Chemotherapy
|
November 1, 2017
<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir
Teresa I Ng, Rakesh Tripathi, Thomas Reisch, et al.
Page
of 9